Market Closed -
Japan Exchange
02:00:00 2024-04-23 am EDT
5-day change
1st Jan Change
826
JPY
-0.84%
+1.35%
-17.56%
Pharma Foods International Co., Ltd. authorizes a Buyback Plan.
The Board of Directors of Pharma Foods International Co., Ltd. has authorized a buyback plan on September 6, 2021.
Pharma Foods International Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending July 31, 2024
Mar. 15
CI
Pharma Foods International Co., Ltd. Announces Dividend for the Second Quarter of the Fiscal Year Ending July 31, 2024, Payable on April 2, 2024
Mar. 15
CI
Tranche Update on Pharma Foods International Co., Ltd.'s Equity Buyback Plan announced on January 5, 2024.
Jan. 22
CI
Pharma Foods International Co., Ltd.'s Equity Buyback announced on January 5, 2024, has closed with 874,100 shares, representing 3.03% for ¥999.9 million.
Jan. 18
CI
Pharma Foods International Co., Ltd. announces an Equity Buyback for 1,100,000 shares, representing 3.8% for ¥1,000 million.
Jan. 05
CI
Pharma Foods International Co., Ltd. authorizes a Buyback Plan.
Jan. 04
CI
Pharma Foods International Return to the Black in Fiscal Q1
Dec. 12
MT
Pharma Foods International Co., Ltd. Provides Dividend Guidance for the Second Quarter of Fiscal Year Ending July 31, 2024
Dec. 12
CI
Pharma Foods International Co., Ltd. Provides Dividend Guidance for the Year Ending July 31, 2024
Dec. 12
CI
Pharma Foods International Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending July 31, 2024
Dec. 12
CI
Pharma Foods International Co., Ltd. agreed to acquire Healthcare Mail Order Business Of Daicel from Daicel Corporation.
23-09-19
CI
Pharma Foods International Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending July 31, 2024
23-09-10
CI
Pharma Foods International Co., Ltd. Reports Dividend Result for the Second Quarter Ending July 31, 2023; Provides Dividend Guidance for the Second Quarter Ending July 31, 2024
23-09-10
CI
Pharma Foods International Co., Ltd. Reports Dividend Result for year Ending July 31, 2023, Payable on October 26, 2023
23-09-10
CI
Pharma Foods International Co., Ltd. Expects Dividend for the Year Ending July 31, 2024
23-09-10
CI
Pharma Foods International Co., Ltd. Provides Dividend Guidance for the Year Ending July 31, 2023
23-06-06
CI
Pharma Foods International Co., Ltd. Reports Earnings Results for the Nine Months Ended April 30, 2023
23-06-04
CI
Pharma Foods International Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending July 31, 2023
23-06-04
CI
Pharma Foods International Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending July 31, 2023
23-03-08
CI
Pharma Foods International Co., Ltd. completed the acquisition of the Bioscience Business of Integrale Co Ltd. for ¥140 million.
22-12-11
CI
Pharma Foods International Turns to Fiscal Q1 Loss on Higher Expenses
22-12-08
MT
Pharma Foods International Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending July 31, 2023
22-12-06
CI
Pharma Foods International Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending July 31, 2023
22-12-06
CI
Tranche Update on Pharma Foods International Co., Ltd.'s Equity Buyback Plan announced on October 7, 2022.
22-10-25
CI
Pharma Foods International Co., Ltd.'s Equity Buyback announced on October 7, 2022, has closed with 242,200 shares, representing 0.83% for ¥299.98 million.
22-10-23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Pharma Foods International Co., Ltd. is a Japan-based company mainly engaged in mail order business and functional materials business. The Company operates through three business segments. The Mail Order segment is engaged in the sale of supplement Tamagosamin, cosmetics Pearl Skin Lanchel and Derma QII Mild Peeling Gel, through advertising media such as televisions and radios. The Functional Materials segment is engaged in the development and sale of functional materials such as GABA, Bonepep, Folic Acid eggs and Chicken Egg Antibody. The Company is also engaged in the planning and sale of original equipment manufacturer (OEM) products such as supplements and beverages. The Biomedical segment is engaged in the antibody contract manufacture business for drug discovery and diagnostics, and life science information (LSI) business for analysis and efficacy evaluation test of materials and products.
More about the company
1st Jan change
Capi.
-17.56% 151M +2.04% 42.11B +48.83% 40.08B +7.89% 40B -10.82% 26.87B +7.82% 24.58B -23.61% 18.44B +1.41% 11.94B +31.27% 11.66B +7.21% 11.01B
Other Biotechnology & Medical Research
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
PHARMA FOODS INTERNATIONAL CO., LTD. 
